Olaparib and durvalumab in metastatic BRCA wild type triplenegative breast cancer

Olaparib and durvalumab in metastatic BRCA wild type triple-negative breast cancer

09:05 EDT 6 Jun 2019 | ecancermedicalscience

Dr Zahi Mitri talks to ecancer at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting about results from a trial looking at olaparib and durvalumab in metastatic BRCA wild type triple-negative breast cancer. He explains that olaparib is...

More From BioPortfolio on "Olaparib and durvalumab in metastatic BRCA wild type triple-negative breast cancer"